Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Early and late apoptosis protein expression (Bcl-2, BAX and p53) in traumatic brachial plexus injury

Suroto H., Asriel A., De Vega B., Samijo SK.

Prospective Study, published in J Musculoskelet Neuronal Interact (2021) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Musculoskelet Neuronal Interact (2021)
Reported sample size
—
Source database
Europe PMC
PMID
34854392
PMCID
PMC8672401
Citations
12

Abstract (original English)

Objectives This research aims to analyze the expression of pro-apoptotic proteins (Bax, p53) and anti-apoptotic protein (Bcl-2) in the nerve roots of the brachial plexus following traumatic brachial plexus injury (TBPI) in the early and late stage. Methods A total of 30 biopsy samples were taken from the proximal stump of the postganglionic nerve roots of the TBPI patients' brachial plexus from January 2018 until September 2019. The samples were taken from patients within six months of trauma (early stage, group A) and more than six months following trauma (late stage, group B). Bcl-2, Bax, and p53 expressions in each group were measured and compared. Results We found significant differences in the Bcl-2 (p=0.04), Bax (p Conclusion Apoptosis is inhibited by Bcl-2 activities in the early stage following trauma. In the late stage, a significant decrease of Bcl-2 coupled with a substantial increase of Bax and p53 indicates a continuation of the apoptotic process.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Brachial PlexusHumansProto-Oncogene Proteins c-bcl-2ApoptosisTumor Suppressor Protein p53bcl-2-Associated X Protein

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.